PMID- 37252087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230531
IS  - 1735-5370 (Print)
IS  - 2008-2371 (Electronic)
IS  - 1735-5370 (Linking)
VI  - 17
IP  - 3
DP  - 2022 Jul
TI  - Mid to Long-Term Echocardiographic Follow-up of Patients Undergoing Transcatheter 
      Tricuspid Valve-in-Valve Replacement for Degenerated Bioprosthetic Valves: First 
      Single-Center Report from Iran.
PG  - 112-118
LID - 10.18502/jthc.v17i3.10843 [doi]
AB  - BACKGROUND: Transcatheter tricuspid valve-in-valve (TTViV) replacement has become 
      an alternative treatment in high-risk patients with bioprosthetic valve 
      degeneration. This is the first report on the mid to long-term echocardiographic 
      findings of patients who underwent TTViV replacement in a cardiac referral center 
      in Iran. METHODS: Data of 12 patients, consisting of 11 women and 1 man, who 
      underwent TTViV replacement between 2015 and 2021 were reviewed retrospectively. 
      The patients underwent echocardiography before the procedure and at a mean 
      follow-up time of 3.17+/-1.75 years. RESULTS: All the patients had New York Heart 
      Association (NYHA) function class III/IV before TTViV. Six patients had tricuspid 
      regurgitation, 1 had tricuspid stenosis, and 5 had both. All the patients had 
      successful TTViV. The mean time from the initial valve surgery to TTViV was 
      6.25+/-2.45 years. At follow-up, 2 patients had died: 1 due to COVID-19 pneumonia 
      and 1 without a known cause. The remaining 10 patients experienced improvements 
      in the NYHA functional class. Echocardiographic measures showed significant 
      improvements. Transvalvular mean gradient pressure decreased from 7.08+/-1.98 mm Hg 
      to 5.29+/-1.63 mm Hg (P=0.028), tricuspid valve pressure half time decreased from 
      245.00+/-49.46 ms to 158.64+/-57.41 ms (P=0.011), tricuspid regurgitation gradient 
      decreased from 39.91+/-7.31 mm Hg to 26.72+/-8.99 mm Hg, and left ventricular 
      ejection fraction increased from 47.71+/-4.70% to 49.79+/-4.58% (P=0.046). There was 
      no significant paravalvular or transvalvular leakage at follow-up. CONCLUSION: 
      This is a single-center report on the mid and long-term echocardiographic 
      follow-up of patients after TTViV replacement. Our study showed that TTViV was a 
      safe and efficient method in treating high-risk patients with degenerated 
      bioprosthetic tricuspid valves and had favorable echocardiographic and clinical 
      results.
CI  - Copyright (c) 2022 Tehran University of Medical Sciences. Published by Tehran 
      University of Medical Sciences.
FAU - Sahebjam, Mohammad
AU  - Sahebjam M
AD  - Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Haji Zeinali, Alimohammad
AU  - Haji Zeinali A
AD  - Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Abbasi, Kyomars
AU  - Abbasi K
AD  - Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Borjian, Solmaz
AU  - Borjian S
AD  - Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Iran
TA  - J Tehran Heart Cent
JT  - The journal of Tehran Heart Center
JID - 101289255
PMC - PMC10222937
OTO - NOTNLM
OT  - Bioprosthesis
OT  - Echocardiography
OT  - Tricuspid valve insufficiency
OT  - Tricuspid valve stenosis
EDAT- 2023/05/30 13:07
MHDA- 2023/05/30 13:08
PMCR- 2022/07/01
CRDT- 2023/05/30 11:49
PHST- 2022/03/12 00:00 [received]
PHST- 2022/05/21 00:00 [accepted]
PHST- 2023/05/30 13:08 [medline]
PHST- 2023/05/30 13:07 [pubmed]
PHST- 2023/05/30 11:49 [entrez]
PHST- 2022/07/01 00:00 [pmc-release]
AID - JTHC-17-112 [pii]
AID - 10.18502/jthc.v17i3.10843 [doi]
PST - ppublish
SO  - J Tehran Heart Cent. 2022 Jul;17(3):112-118. doi: 10.18502/jthc.v17i3.10843.